Effects of entecavir on tear secretion and tear film function in patients with hepatitis B virus infection
10.3760/cma.j.cn341190-20250101-00002
- VernacularTitle:恩替卡韦对乙型病毒性肝炎患者泪液分泌和泪膜功能的影响
- Author:
Weiping HU
1
;
Liyang NI
1
;
Huangfang YING
1
;
Zilong ZHANG
1
;
Yonggen XU
1
Author Information
1. 绍兴文理学院附属医院眼科，绍兴 312000
- Publication Type:Journal Article
- Keywords:
Hepatitis B;
Xerophthalmia;
Tears;
Lacrimal apparatus;
Entecavir
- From:
Chinese Journal of Primary Medicine and Pharmacy
2025;32(10):1509-1512
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To analyze the effects of entecavir on tear secretion and tear film function in patients with hepatitis B virus (HBV) infection.Methods:A retrospective analysis was conducted on the clinical data of 24 patients with HBV infection who received treatment with entecavir at the Department of Ophthalmology, Affiliated Hospital of Shaoxing University from April to October 2022. The relevant examination results of dry eye in these patients were analyzed before medication and at 1 and 3 months after medication.Results:Before medication, 13 cases (54.17%) had dry eye, and 3 months after medication, 17 cases (70.83%) had dry eye. At 1 and 3 months after treatment with entecavir, the Ocular Surface Disease Index values of the patients were (13.83 ± 7.11) points and (15.29 ± 6.94) points, respectively. There was no significant difference in Ocular Surface Disease Index value between before and after treatment ( t = -0.24, -1.24, both P>0.05). At 1 and 3 months after treatment, the Schirmer I test results were (8.74 ± 2.40) mm and (8.21 ± 2.40) mm, respectively. The Schirmer I test results at 3 months after treatment were significantly lower than those before treatment ( t = 2.12, P<0.05). At 3 months after treatment, the tear film break-up time was reduced to (7.63 ± 1.97) seconds, which was significantly shorter than the value recorded before treatment ( t = 2.12, P<0.05). At 3 months after treatment, the height of the tear meniscus was (0.21 ± 0.06) mm, which was significantly different from that measured before treatment ( t = 2.26, P<0.05).At 3 months after treatment, the red eye index increased compared with the value recorded before treatment, but the difference was not statistically significant ( t = -0.35, -0.94, both P>0.05). Conclusions:Patients with HBV infection are prone to developing dry eye syndrome. After treatment with entecavir, there may be a reduction in tear secretion and a decline in tear film function, which should be a concern for clinicians.
